— Report will be subject of CTAF meeting in Feburary 2021; Open Input now being accepted until July 15, 2020 — BOSTON, June 26, 2020 – The Institute for Clinical and Economic Review (ICER) announced today that it will assess the comparative clinical effectiveness and value of roxadustat (FibroGen, Inc.) for treatment of anemia in chronic kidney […]
Read More
06/26/2020
— Document open to public comment until August 7, 2020 — BOSTON, July 20, 2020 – The Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of treatments for anemia in chronic kidney disease. ICER’s report will focus on roxadustat (FibroGen, Inc), which is currently […]
Read More
07/20/2020
— Oral GLP-1 semaglutide achieves commonly cited thresholds for cost-effectiveness but is less cost-effective than SGLT-2 competitor empagliflozin — — Independent appraisal committee votes that oral semaglutide provides a superior net health benefit over background therapy alone, achieves intermediate long-term value for money, and may be an attractive alternative for patients who would prefer an […]
Read More
12/09/2019
Boston, Mass. August 11, 2015 - The Institute for Clinical and Economic Review (ICER) has posted the final report Controversies in Obesity Management and an accompanying action guide to the California Technology Assessment Forum (CTAF) website. The report evaluates the evidence on the comparative clinical effectiveness and value of multiple surgical, device, and pharmacological treatment […]
Read More
08/11/2015
Public Comments
Closed